Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Frontiers in Pharmacology
J MatthaeiMuhammad Rafehi

Abstract

The tricyclic antidepressant amitriptyline is frequently prescribed but its use is limited by its narrow therapeutic range and large variation in pharmacokinetics. Apart from interindividual differences in the activity of the metabolising enzymes cytochrome P450 (CYP) 2D6 and 2C19, genetic polymorphism of the hepatic influx transporter organic cation transporter 1 (OCT1) could be contributing to interindividual variation in pharmacokinetics. Here, the impact of OCT1 genetic variation on the pharmacokinetics of amitriptyline and its active metabolite nortriptyline was studied in vitro as well as in healthy volunteers and in depressive disorder patients. Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 µM. Thirty other antidepressant and neuroleptic drugs were also found to be moderate to strong OCT1 inhibitors with IC50 values in the micromolar range. However, in 35 healthy volunteers, preselected for their OCT1 genotypes, who received a single dose of 25 mg amitriptyline, no significant effects on amitriptyline and nortriptyline pharmacokinetics could be attributed to OCT1 genetic polymorphism. In contrast, the strong impact of the CYP2D6 genotype on amitriptyline...Continue Reading

References

Oct 1, 1985·Analytical Biochemistry·P K SmithD C Klenk
Oct 1, 1983·Clinical Pharmacology and Therapeutics·B MellströmF Sjöqvist
May 20, 1998·Clinical Pharmacology and Therapeutics·P DalénL Bertilsson
May 13, 1999·Cellular and Molecular Neurobiology·M V Rudorfer, W Z Potter
Mar 4, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M UhrF Holsboer
Nov 24, 2004·Drug Metabolism Reviews·Ursula Breyer-Pfaff
Jan 18, 2006·Drug Metabolism and Pharmacokinetics·Masuhiro Nishimura, Shinsaku Naito
May 2, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·David Hallifax, J Brian Houston
May 2, 2007·British Journal of Pharmacology·P K Gillman
Jan 22, 2008·Journal of Clinical Psychopharmacology·Julia KirchheinerJürgen Brockmöller
Sep 16, 2008·Journal of Medicinal Chemistry·Gustav AhlinPer Artursson
Oct 13, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Jan 1, 1989·Neurochemistry International·P GoldmanW S Messer
Sep 3, 2011·Nature·Karsten SuhreChristian Gieger
Jul 19, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Britta HaenischHeinz Bönisch
Sep 15, 2012·Pakistan Journal of Biological Sciences : PJBS·D Ramakrishna, M N Subhash
Dec 21, 2013·PloS One·Manuel MaiAlexander Benedikt Leichtle
Jul 7, 2015·The Cochrane Database of Systematic Reviews·R Andrew MoorePhilip J Wiffen
Aug 8, 2015·Continuum : Lifelong Learning in Neurology·Stephen D Silberstein
Sep 24, 2015·Expert Review of Neurotherapeutics·Fernando Rico-VillademorosElena P Calandre
Nov 7, 2018·Die Pharmazie·B Sienkiewicz-Oleszkiewicz, A Wiela-Hojeńska
Dec 11, 2019·Cleveland Clinic Journal of Medicine·Joanne SchneiderXavier F Jimenez
Dec 20, 2019·Pharmacological Reviews·Hermann Koepsell

❮ Previous
Next ❯

Software Mentioned

SigmaPlot
Prism

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here